Psoriasis: The Uptake of Stelara in the United States: How are Physicians Integrating this IL-12/23 Inhibitor into a Market Dominated by TNF-alpha Inhibitors?

Based on our Pharmacor advisory service entitled Psoriasis, Decision Resources is offering an exclusive analyst call entitled Psoriasis: The Uptake of Stelara in the United States: How are Physicians Integrating this IL-12/23 Inhibitor into a Market Dominated by TNF-alpha Inhibitors? Because this presentation will feature updates to the Psoriasis topic, it is ONLY available to purchasers of this Pharmacor advisory service.

Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.

Over the past six years, the moderate-to-severe psoriasis market has been dominated by several TNF-alpha inhibitors with varied efficacy and safety profiles. However, the 2009 introduction of Centocor Ortho Biotech/Janssen-Cilag’s Stelara (ustekinumab), a first-in-class interleukin (IL) 12/23 inhibitor, to the U.S. and European markets, may pose a potential threat to this dominance. In the first head-to-head trial between two biologics, Stelara showed superior efficacy over Amgen/Pfizer/Takeda’s Enbrel, which has enjoyed the reputation of market leader since its approval for psoriasis in 2004. While Stelara boasts a more convenient dosing regimen, the lack of long-term safety and efficacy data may hinder its prospects for overshadowing the TNF dominance.

Decision Resources recently conducted a survey of 30 U.S. dermatologists in order to assess the uptake of Stelara in the months following its launch and to evaluate what physicians perceive to be incentives and deterrents in their prescribing of the drug.

This 15-minute analyst call, presented by Decision Resources Analyst Iva Holder, Ph.D., will answer the following questions:

• Where does Stelara currently fit in the treatment algorithm for moderate-to-severe psoriasis?
• Can Stelara become a first-line treatment for psoriasis and which biologics are at most risk of being replaced by it?
• What are some of the major barriers to dermatologists’ prescribing of Stelara?
• How are physicians’ prescribing practices influenced by the requirement for healthcare provider administration, infrequent dosing schedule, and Stelara’s head-to-head trial against Enbrel?

Dr. Holder will conduct a live Q & A session after the presentation.

Registration

Psoriasis: Uptake of Stelara in the United States: How are Physicians Integrating this IL-12/23 Inhibitor into a Market Dominated by TNF-alpha Inhibitors?

June 15, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.

Contact Us

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.